Skip to main content
. Author manuscript; available in PMC: 2022 Jun 14.
Published in final edited form as: Sci Transl Med. 2021 Nov 24;13(621):eabl4580. doi: 10.1126/scitranslmed.abl4580

Fig. 2. AAV-DREADD increases hippocampal cAMP and influences behavior.

Fig. 2.

(A) Hippocampal cAMP production in animals injected with hippocampal AAV-DREADD and intraperitoneal CNO. A 2 × 2 ANOVA showed an interaction between virus (none/AAV-DREADD) and intraperitoneal injection (saline/CNO): F1,16 = 5.0492, P = 0.0391, n = 5, 5, 5, and 5. (B) Representative current clamp recording from a GFP+ CA1 pyramidal neuron at a holding potential of −70 mV in the presence or absence of CNO. Quantified in (C) (pre-CNO: 1.24 ± 0.02; post-CNO: 1.32 ± 0.03; paired t test, t6 = −3.26, P = 0.017, n = 7, N = 5). (D) Wild-type male and female mice were bilaterally injected with AAV-DREADD and received either intraperitoneal CNO or saline (NS) before TST [(D) male NS: 120.2 ± 8.3 s, n = 9; male CNO: 177.0 ± 10.2 s, n = 7; female NS: 137.7 ± 13.6 s, n = 11; female CNO: 187.4 ± 11.5 s, n = 11; means ± SEM] and FST [(E) male NS: 103.5 ± 9.0 s, n = 9; male CNO: 143.6 ± 9.1 s, n = 9; female NS: 79.4 ± 8.6 s, n = 15; female CNO: 117.6 ± 11.0 s, n = 13]. (F) Schematic for the object location memory (OLM) task, adapted from Maroso et al. (18). Either intraperitoneal CNO or intraperitoneal saline was administered immediately after training. (G) OLM performance from male and female mice bilaterally injected with AAV-DREADD after intraperitoneal saline or CNO is administered (male NS: 0.08 ± 0.05, n = 14; male CNO: −0.14 ± 0.05, n = 13; female NS: 0.28 ± 0.05, n = 15; female CNO: 0.04 ± 0.06, n = 14). *P < 0.05 for (D), (E), and (G). Asterisk denotes main effect of “NS/CNO”; see supplementary tables for details.